These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 18957342

  • 1. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
    Smach MA, Charfeddine B, Lammouchi T, Dridi H, Ben Othman L, Bennamou S, Limem K.
    Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, Ltaief A, Bennamou S, Limem K.
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [Abstract] [Full Text] [Related]

  • 3. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 5. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2007 Jul 15; 12(7):671-80. PubMed ID: 17339876
    [Abstract] [Full Text] [Related]

  • 6. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K.
    Arch Gen Psychiatry; 2004 Jan 15; 61(1):95-102. PubMed ID: 14706948
    [Abstract] [Full Text] [Related]

  • 7. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.
    Neurobiol Aging; 2006 Sep 15; 27(9):1202-11. PubMed ID: 16085339
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
    Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E.
    Alzheimers Dement; 2010 Mar 15; 6(2):104-9. PubMed ID: 20298970
    [Abstract] [Full Text] [Related]

  • 9. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Neurodegener Dis; 2007 Mar 15; 4(5):366-75. PubMed ID: 17622779
    [Abstract] [Full Text] [Related]

  • 10. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
    Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J.
    J Neurochem; 2007 Oct 15; 103(2):467-74. PubMed ID: 17662050
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF.
    Neurosci Lett; 2007 Oct 15; 383(1-2):12-6. PubMed ID: 15936505
    [Abstract] [Full Text] [Related]

  • 12. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 13. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S.
    Neurochem Int; 2009 Sep 21; 55(4):214-8. PubMed ID: 19524111
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, Yébenes JG, del Ser T.
    Arch Neurol; 2003 Sep 21; 60(9):1218-22. PubMed ID: 12975286
    [Abstract] [Full Text] [Related]

  • 15. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E, Egrilmez MY, Keskinoglu P, Cavdar Z, Genc S, Genc K, Iyilikci L, Yener GG.
    Cell Biochem Funct; 2009 Aug 21; 27(6):395-401. PubMed ID: 19639578
    [Abstract] [Full Text] [Related]

  • 16. [Biochemical markers for Alzheimer disease].
    Czarna JM, Waldemar G, Heegaard NH.
    Ugeskr Laeger; 2006 Mar 06; 168(10):1010-4. PubMed ID: 16522291
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P, Battisti C, Radi E, Federico A.
    J Cell Physiol; 2006 Jul 06; 208(1):39-46. PubMed ID: 16447254
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 06; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 19. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.
    J Alzheimers Dis; 2011 Mar 06; 27(2):377-84. PubMed ID: 21841257
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L.
    Funct Neurol; 2008 Mar 06; 23(2):93-6. PubMed ID: 18671910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.